E
Epikast
We are passionate about healthcare and service to patients
About Epikast
Epikast operates in the healthcare sector, specifically partnering with biopharmaceutical companies to enhance patient and caregiver engagement. The company focuses on creating personalized experiences across various communication channels, leveraging behavioral science and cutting-edge technology to maximize the impact of these interactions. Epikast's business model revolves around providing customized patient engagement solutions, which are designed to improve the overall patient experience and outcomes. The company generates revenue through partnerships with biopharmaceutical firms, offering services that are crucial during patient interactions and care processes. Epikast serves a niche market, primarily targeting biopharmaceutical companies and their key stakeholders, including patients, caregivers, and prescribers. By focusing on meaningful human interactions and continuous innovation, Epikast aims to redefine how biopharmaceutical companies engage with their most important stakeholders.
Source: Dealroom company dataAt a glance
- Founded
- 2022
- Headquarters
- New York City, United States
- Sector
- Health Tech & Medtech
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
EcoR1 Capital
Kos Biotechnology Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Epikast on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Epikast on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.